BC Innovations | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
BC Innovations | May 1, 2019
Translation in Brief

White matter matters in Alzheimer’s

An MIT team has identified Alzheimer’s disease-associated changes in gene expression that vary based on cell type, including myelin-related genes, suggesting new pathways that can be explored to treat the disease. Described in a Nature...
BC Innovations | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
BC Extra | Apr 25, 2017
Company News

Biogen climbs as Spinraza sales top consensus

Biogen Inc. (NASDAQ:BIIB) gained $10.03 to $286.89 after it reported 1Q17 earnings that beat a consensus estimate, including stronger than expected sales of Spinraza nusinersen. The company reported $47.4 million in sales of the spinal...
BC Week In Review | Sep 26, 2016
Clinical News

Opicinumab: Additional Phase II data

Additional data from the double-blind, international Phase II SYNERGY trial in 412 evaluable patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS), showed that 10 and 30 mg/kg IV...
BC Extra | Sep 16, 2016
Clinical News

Biogen ties anti-LINGO miss to non-linear dose response

Biogen Inc. (NASDAQ:BIIB) suggested a non-linear dose response to opicinumab ( BIIB033 ) could have led to the compound's failure to meet the primary endpoint in the Phase II SYNERGY study to treat relapsing forms of multiple...
BC Innovations | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BioCentury | Jul 11, 2016

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
BioCentury | Jun 20, 2016
Product Development

Translating LINGO

Biogen Inc. isn't talking yet about why its anti-LINGO mAb failed a Phase II trial in the high-priority indication of multiple sclerosis, but translational researchers in the field have some ideas about knowledge gaps that...
Items per page:
1 - 10 of 44